MEDCAC Review of PGx Cancer Tests Finds Some Clinical Utility, More Evidentiary Gaps

Although CMS does not have a national coverage determination on pharmacogenomic testing in cancer, a CMS advisory committee met last week in Baltimore, Md., to discuss whether five tests are clinically useful in the Medicare population.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.